Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.

PURPOSE Homoharringtonine (HHT) is commonly used for the treatment of Chinese adult AML, and all-trans retinoic acid (ATRA) has been verified in acute promyelocytic leukemia (APL). However, the efficacy and safety of HHT-based induction therapy have not been confirmed for childhood AML, and ATRA-based treatment has not been evaluated among patients with non-APL AML. PATIENTS AND METHODS This open-label, multicenter, randomized Chinese Children's Leukemia Group-AML 2015 study was performed across 35 centers in China. Patients with newly diagnosed childhood AML were first randomly assigned to receive an HHT-based (H arm) or etoposide-based (E arm) induction regimen and then randomly allocated to receive cytarabine-based (AC arm) or ATRA-based (AT arm) maintenance therapy. The primary end points were the complete remission (CR) rate after induction therapy, and the secondary end points were the overall survival (OS) and event-free survival (EFS) at 3 years. RESULTS We enrolled 1,258 patients, of whom 1,253 were included in the intent-to-treat analysis. The overall CR rate was significantly higher in the H arm than in the E arm (79.9% v 73.9%, P = .014). According to the intention-to-treat analysis, the 3-year OS was 69.2% (95% CI, 65.1 to 72.9) in the H arm and 62.8% (95% CI, 58.7 to 66.6) in the E arm (P = .025); the 3-year EFS was 61.1% (95% CI, 56.8 to 65.0) in the H arm and 53.4% (95% CI, 49.2 to 57.3) in the E arm (P = .022). Among the per-protocol population, who received maintenance therapy, the 3-year EFS did not differ significantly across the four arms (H + AT arm: 70.7%, 95% CI, 61.1 to 78.3; H + AC arm: 74.8%, 95% CI, 67.0 to 81.0, P = .933; E + AC arm: 72.9%, 95% CI, 65.1 to 79.2, P = .789; E + AT arm: 66.2%, 95% CI, 56.8 to 74.0, P = .336). CONCLUSION HHT is an alternative combination regimen for childhood AML. The effects of ATRA-based maintenance are comparable with those of cytarabine-based maintenance therapy.

[1]  S. Miyano,et al.  Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia , 2022, Blood advances.

[2]  R. Ribeiro,et al.  Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study. , 2021, Blood advances.

[3]  J. Downing,et al.  DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML , 2020, Cancers.

[4]  S. Shen,et al.  Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia , 2019, Frontiers of Medicine.

[5]  D. Reinhardt,et al.  Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012 , 2018, Leukemia.

[6]  K. Uchimaru,et al.  Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature Review , 2017, Internal medicine.

[7]  K. Döhner,et al.  All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study , 2016, Annals of Hematology.

[8]  Kailin Xu,et al.  Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein , 2016, Cancer medicine.

[9]  R. Hills,et al.  A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia , 2016, Leukemia.

[10]  Ya-Zhen Qin,et al.  Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21). , 2016, Leukemia research.

[11]  R. Hills,et al.  The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial , 2014, Leukemia.

[12]  C. Chung.  Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  Z. Estrov,et al.  A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. , 2013, European journal of cancer care.

[14]  S. Meshinchi,et al.  Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia , 2013, Pediatric blood & cancer.

[15]  S. Ezoe,et al.  Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor , 2012, International journal of environmental research and public health.

[16]  J. Rubnitz.  How I treat pediatric acute myeloid leukemia. , 2012, Blood.

[17]  Martin Dugas,et al.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia , 2012, Nature Medicine.

[18]  Jie Jin,et al.  Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience , 2011, Annals of Hematology.

[19]  Jingyan Tang,et al.  Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China , 2011, International journal of hematology.

[20]  R. Hills,et al.  The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. , 2010, Blood.

[21]  Xiao Li,et al.  Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome , 2009, Leukemia & lymphoma.

[22]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[23]  Jian Huang,et al.  Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia , 2006, Leukemia.

[24]  A. Burnett,et al.  Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. , 2006, Blood.

[25]  R. Hills,et al.  Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials , 2005, Leukemia.

[26]  U. Creutzig,et al.  Pediatric acute myeloid leukemia: international progress and future directions , 2005, Leukemia.

[27]  S. Fröhling,et al.  Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia , 2004, Leukemia.

[28]  Jin Jie,et al.  Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro‐apoptotic bax and inducing caspase‐3‐mediated cleavage of poly(ADP‐ribose) polymerase (PARP) , 2004, American journal of hematology.

[29]  D. Green,et al.  Secondary Acute Myelogenous Leukemia in Patients Previously Treated for Childhood Renal Tumors: A Report From the National Wilms Tumor Study Group , 2001, Journal of pediatric hematology/oncology.

[30]  M. Oken,et al.  Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483) , 2000, Leukemia.

[31]  P. Koistinen,et al.  p53 Pathway in Apoptosis Induced by All-Trans-Retinoic Acid in Acute Myeloblastic Leukaemia Cells , 2000, Acta Haematologica.

[32]  Ø. Bruserud,et al.  New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction—Present Use and Future Possibilities , 2000, Stem cells.

[33]  M. Tribalto,et al.  A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes , 2000, Annals of Hematology.

[34]  S. Waxman.  Differentiation therapy in acute myelogenous leukemia (non-APL) , 2000, Leukemia.

[35]  John Calvin Reed,et al.  Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid , 1999, Leukemia.

[36]  A. Pileri,et al.  Combined differentiating therapy for myelodysplastic syndromes: a phase II study. , 1996, Leukemia research.

[37]  W. Qian,et al.  Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB. , 2016, Oncology letters.

[38]  H. Dombret,et al.  All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. , 2002, The hematology journal : the official journal of the European Haematology Association.

[39]  R. Mertelsmann,et al.  Acute myelomonocytic leukemia secondary to synchronous carcinomas of the breast and lung, and to metachronous renal cell carcinoma , 1997, Journal of Cancer Research and Clinical Oncology.